BamSEC and AlphaSense Join Forces
Learn More

Lantheus Medical Imaging, Inc.

Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 20 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 1 page Amendment to Lantheus Holdings, Inc. 2013 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.51
from 10-K 2 pages February 6, 2014 Pharmalucence, Inc. 29 Dunham Road Billerica, Ma 01862 Attention: Edward J. Connolly, Chief Operating Officer
12/34/56
EX-10.50
from 10-K 13 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Settlement and Release Agreement
12/34/56
EX-10.49
from 10-K 27 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission
12/34/56
EX-10.48
from 10-K 16 pages Employment Agreement
12/34/56
EX-10.47
from 10-K 16 pages Employment Agreement
12/34/56
EX-10.46
from 10-K 5 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 24 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Fissionmo-99 Supply Agreement
12/34/56
EX-10.3
from 8-K 20 pages Lantheus MI Holdings, Inc. 2013 Equity Incentive Plan Non-Employee Director Option Grant Award Agreement
12/34/56
EX-10.2
from 8-K 27 pages Lantheus MI Holdings, Inc. 2013 Equity Incentive Plan Option Grant Award Agreement
12/34/56
EX-10.1
from 8-K 19 pages Lantheus MI Holdings, Inc. 2013 Equity Incentive Plan Effective as of April 30, 2013
12/34/56
EX-10.57
from 10-K 11 pages Confidential Separation and Consulting Agreement and General Release
12/34/56
EX-10.56
from 10-K 35 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission
12/34/56
EX-10.55
from 10-K 4 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Amendment No. 2 to Amended and Restated Cardiolite® License and Supply Agreement
12/34/56
EX-10.54
from 10-K 9 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Amendment No. 2 to Amended and Restated Supply Agreement
12/34/56
EX-10.53
from 10-K 11 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission
12/34/56
EX-10.52
from 10-K 8 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission
12/34/56